Early noninvasive detection of response to targeted therapy in non–small cell lung cancer

Jillian Phallen, Alessandro Leal, Brian D. Woodward, Patrick Forde, Jarushka Naidoo, Kristen Marrone, Julie Brahmer, Jacob Fiksel, Jamie E. Medina, Stephen Cristiano, Doreen N. Palsgrove, Christopher Gocke, Daniel C. Bruhm, Parissa Keshavarzian, Vilmos Adleff, Elizabeth Weihe, Valsamo Anagnostou, Robert B Scharpf, Victor E Velculescu, Hatim Husain

Research output: Contribution to journalArticle

Abstract

With the advent of precision oncology, there is an urgent need to develop improved methods for rapidly detecting responses to targeted therapies. Here, we have developed an ultrasensitive measure of cell-free tumor load using targeted and whole-genome sequencing approaches to assess responses to tyrosine kinase inhibitors in patients with advanced lung cancer. Analyses of 28 patients treated with anti-EGFR or HER2 therapies revealed a bimodal distribution of cell-free circulating tumor DNA (ctDNA) after therapy initiation, with molecular responders having nearly complete elimination of ctDNA (>98%). Molecular nonresponders displayed limited changes in ctDNA levels posttreatment and experienced significantly shorter progression-free survival (median 1.6 vs. 13.7 months, P < 0.0001; HR ¼ 66.6; 95% confidence interval, 13.0–341.7), which was detected on average 4 weeks earlier than CT imaging. ctDNA analyses of patients with radiographic stable or nonmeasurable disease improved prediction of clinical outcome compared with CT imaging. These analyses provide a rapid approach for evaluating therapeutic response to targeted therapies and have important implications for the management of patients with cancer and the development of new therapeutics.

Original languageEnglish (US)
Pages (from-to)1204-1213
Number of pages10
JournalCancer Research
Volume79
Issue number6
DOIs
StatePublished - Jan 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
DNA
Neoplasms
Circulating Neoplastic Cells
Therapeutics
Tumor Burden
Genetic Therapy
Protein-Tyrosine Kinases
Disease-Free Survival
Lung Neoplasms
Genome
Confidence Intervals

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Early noninvasive detection of response to targeted therapy in non–small cell lung cancer. / Phallen, Jillian; Leal, Alessandro; Woodward, Brian D.; Forde, Patrick; Naidoo, Jarushka; Marrone, Kristen; Brahmer, Julie; Fiksel, Jacob; Medina, Jamie E.; Cristiano, Stephen; Palsgrove, Doreen N.; Gocke, Christopher; Bruhm, Daniel C.; Keshavarzian, Parissa; Adleff, Vilmos; Weihe, Elizabeth; Anagnostou, Valsamo; Scharpf, Robert B; Velculescu, Victor E; Husain, Hatim.

In: Cancer Research, Vol. 79, No. 6, 01.01.2019, p. 1204-1213.

Research output: Contribution to journalArticle

Phallen, J, Leal, A, Woodward, BD, Forde, P, Naidoo, J, Marrone, K, Brahmer, J, Fiksel, J, Medina, JE, Cristiano, S, Palsgrove, DN, Gocke, C, Bruhm, DC, Keshavarzian, P, Adleff, V, Weihe, E, Anagnostou, V, Scharpf, RB, Velculescu, VE & Husain, H 2019, 'Early noninvasive detection of response to targeted therapy in non–small cell lung cancer', Cancer Research, vol. 79, no. 6, pp. 1204-1213. https://doi.org/10.1158/0008-5472.CAN-18-1082
Phallen, Jillian ; Leal, Alessandro ; Woodward, Brian D. ; Forde, Patrick ; Naidoo, Jarushka ; Marrone, Kristen ; Brahmer, Julie ; Fiksel, Jacob ; Medina, Jamie E. ; Cristiano, Stephen ; Palsgrove, Doreen N. ; Gocke, Christopher ; Bruhm, Daniel C. ; Keshavarzian, Parissa ; Adleff, Vilmos ; Weihe, Elizabeth ; Anagnostou, Valsamo ; Scharpf, Robert B ; Velculescu, Victor E ; Husain, Hatim. / Early noninvasive detection of response to targeted therapy in non–small cell lung cancer. In: Cancer Research. 2019 ; Vol. 79, No. 6. pp. 1204-1213.
@article{3c4ebcd1b2034396ab51b95ccbaea5cf,
title = "Early noninvasive detection of response to targeted therapy in non–small cell lung cancer",
abstract = "With the advent of precision oncology, there is an urgent need to develop improved methods for rapidly detecting responses to targeted therapies. Here, we have developed an ultrasensitive measure of cell-free tumor load using targeted and whole-genome sequencing approaches to assess responses to tyrosine kinase inhibitors in patients with advanced lung cancer. Analyses of 28 patients treated with anti-EGFR or HER2 therapies revealed a bimodal distribution of cell-free circulating tumor DNA (ctDNA) after therapy initiation, with molecular responders having nearly complete elimination of ctDNA (>98{\%}). Molecular nonresponders displayed limited changes in ctDNA levels posttreatment and experienced significantly shorter progression-free survival (median 1.6 vs. 13.7 months, P < 0.0001; HR ¼ 66.6; 95{\%} confidence interval, 13.0–341.7), which was detected on average 4 weeks earlier than CT imaging. ctDNA analyses of patients with radiographic stable or nonmeasurable disease improved prediction of clinical outcome compared with CT imaging. These analyses provide a rapid approach for evaluating therapeutic response to targeted therapies and have important implications for the management of patients with cancer and the development of new therapeutics.",
author = "Jillian Phallen and Alessandro Leal and Woodward, {Brian D.} and Patrick Forde and Jarushka Naidoo and Kristen Marrone and Julie Brahmer and Jacob Fiksel and Medina, {Jamie E.} and Stephen Cristiano and Palsgrove, {Doreen N.} and Christopher Gocke and Bruhm, {Daniel C.} and Parissa Keshavarzian and Vilmos Adleff and Elizabeth Weihe and Valsamo Anagnostou and Scharpf, {Robert B} and Velculescu, {Victor E} and Hatim Husain",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-18-1082",
language = "English (US)",
volume = "79",
pages = "1204--1213",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Early noninvasive detection of response to targeted therapy in non–small cell lung cancer

AU - Phallen, Jillian

AU - Leal, Alessandro

AU - Woodward, Brian D.

AU - Forde, Patrick

AU - Naidoo, Jarushka

AU - Marrone, Kristen

AU - Brahmer, Julie

AU - Fiksel, Jacob

AU - Medina, Jamie E.

AU - Cristiano, Stephen

AU - Palsgrove, Doreen N.

AU - Gocke, Christopher

AU - Bruhm, Daniel C.

AU - Keshavarzian, Parissa

AU - Adleff, Vilmos

AU - Weihe, Elizabeth

AU - Anagnostou, Valsamo

AU - Scharpf, Robert B

AU - Velculescu, Victor E

AU - Husain, Hatim

PY - 2019/1/1

Y1 - 2019/1/1

N2 - With the advent of precision oncology, there is an urgent need to develop improved methods for rapidly detecting responses to targeted therapies. Here, we have developed an ultrasensitive measure of cell-free tumor load using targeted and whole-genome sequencing approaches to assess responses to tyrosine kinase inhibitors in patients with advanced lung cancer. Analyses of 28 patients treated with anti-EGFR or HER2 therapies revealed a bimodal distribution of cell-free circulating tumor DNA (ctDNA) after therapy initiation, with molecular responders having nearly complete elimination of ctDNA (>98%). Molecular nonresponders displayed limited changes in ctDNA levels posttreatment and experienced significantly shorter progression-free survival (median 1.6 vs. 13.7 months, P < 0.0001; HR ¼ 66.6; 95% confidence interval, 13.0–341.7), which was detected on average 4 weeks earlier than CT imaging. ctDNA analyses of patients with radiographic stable or nonmeasurable disease improved prediction of clinical outcome compared with CT imaging. These analyses provide a rapid approach for evaluating therapeutic response to targeted therapies and have important implications for the management of patients with cancer and the development of new therapeutics.

AB - With the advent of precision oncology, there is an urgent need to develop improved methods for rapidly detecting responses to targeted therapies. Here, we have developed an ultrasensitive measure of cell-free tumor load using targeted and whole-genome sequencing approaches to assess responses to tyrosine kinase inhibitors in patients with advanced lung cancer. Analyses of 28 patients treated with anti-EGFR or HER2 therapies revealed a bimodal distribution of cell-free circulating tumor DNA (ctDNA) after therapy initiation, with molecular responders having nearly complete elimination of ctDNA (>98%). Molecular nonresponders displayed limited changes in ctDNA levels posttreatment and experienced significantly shorter progression-free survival (median 1.6 vs. 13.7 months, P < 0.0001; HR ¼ 66.6; 95% confidence interval, 13.0–341.7), which was detected on average 4 weeks earlier than CT imaging. ctDNA analyses of patients with radiographic stable or nonmeasurable disease improved prediction of clinical outcome compared with CT imaging. These analyses provide a rapid approach for evaluating therapeutic response to targeted therapies and have important implications for the management of patients with cancer and the development of new therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85062996650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062996650&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-1082

DO - 10.1158/0008-5472.CAN-18-1082

M3 - Article

C2 - 30573519

AN - SCOPUS:85062996650

VL - 79

SP - 1204

EP - 1213

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 6

ER -